Acurx Pharmaceuticals Stock Forecast, Price & News

Acurx Pharmaceuticals (NASDAQ:ACXP) Frequently Asked Questions

What stocks does MarketBeat like better than Acurx Pharmaceuticals?

Wall Street analysts have given Acurx Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acurx Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acurx Pharmaceuticals?

Acurx Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 96,200 shares, an increase of 24.9% from the August 31st total of 77,000 shares. Based on an average daily volume of 548,800 shares, the short-interest ratio is presently 0.2 days.
View Acurx Pharmaceuticals' Short Interest.

When is Acurx Pharmaceuticals' next earnings date?

Acurx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Acurx Pharmaceuticals.

How were Acurx Pharmaceuticals' earnings last quarter?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) released its quarterly earnings results on Monday, August, 16th. The company reported ($0.57) EPS for the quarter.
View Acurx Pharmaceuticals' earnings history.

Who are Acurx Pharmaceuticals' key executives?

Acurx Pharmaceuticals' management team includes the following people:

• Mr. Robert J. DeLuccia, Co-Founder & Exec. Chairman (Age 75, Pay $342.75k)
• Mr. David P. Luci C.P.A., CPA, J.D., Esq., Co-Founder, Pres, CEO & Director (Age 54, Pay $321.21k)
• Mr. Robert G. Shawah, Co-Founder, CFO & Chief Accounting Officer (Age 54, Pay $90k)

Who are some of Acurx Pharmaceuticals' key competitors?

Some companies that are related to Acurx Pharmaceuticals include Galectin Therapeutics (GALT), Impel NeuroPharma (IMPL), PhaseBio Pharmaceuticals (PHAS), TFF Pharmaceuticals (TFFP), Corvus Pharmaceuticals (CRVS), Sol-Gel Technologies (SLGL), Alzamend Neuro (ALZN), 180 Life Sciences (ATNF), Decibel Therapeutics (DBTX), Oncternal Therapeutics (ONCT), Trevena (TRVN), CorMedix (CRMD), MediciNova (MNOV), Clever Leaves (CLVR) and Flora Growth (FLGC).
View all of ACXP's competitors.

When did Acurx Pharmaceuticals IPO?

(ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO.

What is Acurx Pharmaceuticals' stock symbol?

Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP."

When does the company's lock-up period expire?

Acurx Pharmaceuticals' lock-up period expires on Wednesday, December 22nd. Acurx Pharmaceuticals had issued 2,500,000 shares in its IPO on June 25th. The total size of the offering was $15,000,000 based on an initial share price of $6.00. After the end of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acurx Pharmaceuticals' stock price today?

One share of ACXP stock can currently be purchased for approximately $4.82.

How much money does Acurx Pharmaceuticals make?

Acurx Pharmaceuticals has a market capitalization of $48.77 million.

How many employees does Acurx Pharmaceuticals have?

Acurx Pharmaceuticals employs 3 workers across the globe.

What is Acurx Pharmaceuticals' official website?

The official website for Acurx Pharmaceuticals is www.acurxpharma.com.

How can I contact Acurx Pharmaceuticals?

The company can be reached via phone at 917-533-1469.